Esperion Therapeutics Ownership | Who Owns Esperion Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Esperion Therapeutics Ownership Summary

Esperion Therapeutics is owned by 83.76% institutional investors, 0.68% insiders, and 15.56% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 8.59% of ESPR shares. BB Biotech AG Ord is the top mutual fund, with 5.05% of its assets in Esperion Therapeutics shares.

ESPR Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Esperion Therapeutics	83.76%	0.68%	15.56%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock funding, inc. /de	17.85M	8.59%	$48.92M
Blackrock	13.98M	8.26%	$31.04M
Wasatch advisors lp	15.77M	7.59%	$43.21M
Vanguard group	14.95M	7.54%	$55.30M
Two seas capital lp	11.39M	5.48%	$31.22M
Orbimed advisors	10.57M	5.09%	$28.96M
Two sigma investments, lp	9.46M	4.55%	$25.92M
Marshall wace, llp	7.08M	3.40%	$19.39M
State street	7.06M	3.39%	$19.33M
D. e. shaw	6.54M	3.15%	$17.92M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Meditor group	3.79M	15.57%	$8.42M
Velan capital investment management lp	1.72M	2.95%	$4.71M
Privium fund management b.v.	3.30M	1.88%	$9.04M
Penderfund capital management	3.89M	1.67%	$10.66M
Aigh capital management	4.40M	1.64%	$12.06M
Orbimed advisors	10.57M	0.58%	$28.96M
Two seas capital lp	11.39M	0.44%	$31.22M
Rhenman & partners asset management ab	985.00K	0.33%	$2.70M
Wasatch advisors lp	15.77M	0.29%	$43.21M
Integral health asset management	1.50M	0.27%	$3.98M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	13.98M	0.00%	11.14M
Wasatch advisors lp	15.77M	0.29%	6.32M
Two sigma investments, lp	9.46M	0.02%	4.72M
Orbimed advisors	10.57M	0.58%	4.60M
Ubs group	4.29M	0.00%	3.98M

Top Sellers

Holder	Shares	% Assets	Change
Bellevue group	-	-	-9.69M
Great point partners	-	-	-5.79M
Bank of america corp /de/	1.16M	0.00%	-3.38M
Millennium management	604.35K	0.00%	-3.33M
Indaba capital management	-	-	-3.00M

New Positions

Holder	Shares	% Assets	Change	Value
Armistice capital	3.93M	0.19%	3.93M	$10.77M
Privium fund management b.v.	3.30M	1.88%	3.30M	$9.04M
Vanguard fiduciary trust	1.56M	0.00%	1.56M	$4.29M
Integral health asset management	1.50M	0.27%	1.50M	$3.98M
Rhenman & partners asset management ab	985.00K	0.33%	985.00K	$2.70M

Sold Out

Holder	Change
True wealth design	-1.00
Assetmark	-8.00
Srs capital advisors	-15.00
Td waterhouse canada	-59.00
Farther finance advisors	-90.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	214	0.94%	174,108,919	15.10%	83	1.44%	102	-20.31%	60	81.82%
Dec 31, 2025	137	-31.50%	97,287,936	-9.92%	49	1.63%	75	-29.25%	21	-43.24%
Sep 30, 2025	119	-26.54%	54,298,682	-41.97%	27	1.22%	59	-13.24%	23	-41.03%
Jun 30, 2025	168	-11.58%	98,172,969	-13.34%	49	1.49%	67	-17.28%	44	-21.43%
Mar 31, 2025	190	-7.77%	113,479,021	-9.95%	57	1.38%	82	-8.89%	56	21.74%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
BB Biotech AG Ord	9.94M	5.05%	-
Pender Corporate Bond F	6.36M	3.18%	359.98K
Vanguard US Total Market Shares ETF	6.18M	3.12%	-
Vanguard Total Stock Mkt Idx Inv	7.53M	2.92%	-
iShares Russell 2000 ETF	5.66M	2.20%	47.75K
Wasatch Small Cap Growth Investor	3.81M	1.48%	3.81M
Wasatch Ultra Growth	3.77M	1.46%	-649.26K
Biotech Growth Ord	3.74M	1.45%	-
Pender Corporate Bond A	3.56M	1.38%	-500.00K
Wasatch Micro Cap	3.03M	1.18%	213.07K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 17, 2026	Looker Benjamin	Chief Legal Officer	Sell	$15.43K
Mar 17, 2026	Koenig Sheldon L.	President and CEO	Sell	$69.55K
Mar 17, 2026	Halladay Benjamin	Chief Financial Officer	Sell	$17.38K
Jan 20, 2026	Looker Benjamin	General Counsel	Sell	$4.87K
Dec 17, 2025	Koenig Sheldon L.	President and CEO	Sell	$177.20K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	4
2025 Q4	-	3
2025 Q3	-	5
2025 Q2	-	5
2025 Q1	-	7

ESPR Ownership FAQ

Who Owns Esperion Therapeutics?

Esperion Therapeutics shareholders are primarily institutional investors at 83.76%, followed by 0.68% insiders and 15.56% retail investors. The average institutional ownership in Esperion Therapeutics's industry, Biotech Stocks , is 35.75%, which Esperion Therapeutics exceeds.

Who owns the most shares of Esperion Therapeutics?

Esperion Therapeutics’s largest shareholders are Blackrock funding, inc. /de (17.85M shares, 8.59%), Blackrock (13.98M shares, 8.26%), and Wasatch advisors lp (15.77M shares, 7.59%). Together, they hold 24.44% of Esperion Therapeutics’s total shares outstanding.

Does Blackrock own Esperion Therapeutics?

Yes, BlackRock owns 8.26% of Esperion Therapeutics, totaling 13.98M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 31.04M$. In the last quarter, BlackRock increased its holdings by 11.14M shares, a 392.59% change.

Who is Esperion Therapeutics’s biggest shareholder by percentage of total assets invested?

Meditor group is Esperion Therapeutics’s biggest shareholder by percentage of total assets invested, with 15.57% of its assets in 3.79M Esperion Therapeutics shares, valued at 8.42M$.

Who is the top mutual fund holder of Esperion Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Esperion Therapeutics shares, with 5.05% of its total shares outstanding invested in 9.94M Esperion Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools